These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 9623118)

  • 21. A short-term, multicenter, randomized double-blind dose titration study of the efficacy and anticholinergic side effects of transdermal compared to immediate release oral oxybutynin treatment of patients with urge urinary incontinence.
    Davila GW; Daugherty CA; Sanders SW;
    J Urol; 2001 Jul; 166(1):140-5. PubMed ID: 11435842
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Anticholinergic treatment in the therapy of primary enuresis. Effectiveness of oxybutynin chloride in a controlled clinical study of 58 patients].
    Marconi AM; Felici E; Roggia A; Torelli F
    Pediatr Med Chir; 1985; 7(4):573-6. PubMed ID: 3915547
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The use of salivary stimulant pastilles to improve compliance in women taking oxybutinin hydrochloride for detrusor instability.
    Arango O
    Br J Urol; 1998 Apr; 81(4):652. PubMed ID: 9598656
    [No Abstract]   [Full Text] [Related]  

  • 24. [Assessment of effectiveness of and tolerance to oxybutynin in the treatment of unstable bladder in women].
    Serrano Brambila EA; Quiroga Avila RG; Lorenzo Monterrubio JL; Moreno Aranda J
    Ginecol Obstet Mex; 2000 Apr; 68():174-81. PubMed ID: 10824450
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Transdermal oxybutynin: sticking to the facts.
    Cartwright R; Cardozo L
    Eur Urol; 2007 Apr; 51(4):907-14; discussion 914. PubMed ID: 17157979
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tolterodine: superior tolerability than and comparable efficacy to oxybutynin in individuals 50 years old or older with overactive bladder: a randomized controlled trial.
    Malone-Lee J; Shaffu B; Anand C; Powell C
    J Urol; 2001 May; 165(5):1452-6. PubMed ID: 11342895
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Frequency of wetting is predictive of response to anticholinergic treatment in children with overactive bladder.
    Van Arendonk KJ; Austin JC; Boyt MA; Cooper CS
    Urology; 2006 May; 67(5):1049-53; discussion 1053-4. PubMed ID: 16698366
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Intravesical instillation of oxybutynin in women with idiopathic detrusor instability: a randomised trial.
    Enzelsberger H; Helmer H; Kurz C
    Br J Obstet Gynaecol; 1995 Nov; 102(11):929-30. PubMed ID: 8534633
    [No Abstract]   [Full Text] [Related]  

  • 29. Pharmacokinetics of an oral once-a-day controlled-release oxybutynin formulation compared with immediate-release oxybutynin.
    Gupta SK; Sathyan G
    J Clin Pharmacol; 1999 Mar; 39(3):289-96. PubMed ID: 10073329
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy and safety of oxybutynin transdermal system in spinal cord injury patients with neurogenic detrusor overactivity and incontinence: an open-label, dose-titration study.
    Kennelly MJ; Lemack GE; Foote JE; Trop CS
    Urology; 2009 Oct; 74(4):741-5. PubMed ID: 19628264
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Serious psychological side effect in children taking high doses of deptropine].
    Stricker BH; Prins AM; Schilte PP
    Ned Tijdschr Geneeskd; 1992 Jul; 136(28):1362-5. PubMed ID: 1635602
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Improved efficacy of extended release oxybutynin in children with persistent daytime urinary incontinence converted from regular oxybutynin.
    Van Arendonk KJ; Knudson MJ; Austin JC; Cooper CS
    Urology; 2006 Oct; 68(4):862-5. PubMed ID: 17070368
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacokinetics and pharmacodynamics of once-daily controlled-release oxybutynin and immediate-release oxybutynin.
    Reiz JL; Salem P; Darke AC
    J Clin Pharmacol; 2007 Mar; 47(3):351-7. PubMed ID: 17322147
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy and quality of life outcomes of oxybutynin for treating palmar hyperhidrosis in children younger than 14 years old.
    Wolosker N; Schvartsman C; Krutman M; Campbell TP; Kauffman P; de Campos JR; Puech-Leão P
    Pediatr Dermatol; 2014; 31(1):48-53. PubMed ID: 23627681
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A double-blind randomized dose-response study comparing daily doses of 5, 10 and 15 mg controlled-release oxybutynin: balancing efficacy with severity of dry mouth.
    Corcos J; Casey R; Patrick A; Andreou C; Miceli PC; Reiz JL; Harsanyi Z; Darke AC;
    BJU Int; 2006 Mar; 97(3):520-7. PubMed ID: 16469019
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Can oxybutynin cause peripheral neuropathy?
    Patel HR; Albehussi S; Arya M; Miller RA
    J Urol; 2002 Aug; 168(2):646. PubMed ID: 12131334
    [No Abstract]   [Full Text] [Related]  

  • 37. Oxybutynin dependence: a case presentation.
    Mutlu EA
    Turk Psikiyatri Derg; 2011; 22(2):131-2. PubMed ID: 21780343
    [No Abstract]   [Full Text] [Related]  

  • 38. Oxybutynin transdermal system improves the quality of life in adults with overactive bladder: a multicentre, community-based, randomized study.
    Sand P; Zinner N; Newman D; Lucente V; Dmochowski R; Kelleher C; Dahl NV
    BJU Int; 2007 Apr; 99(4):836-44. PubMed ID: 17187655
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The use of salivary stimulant pastilles to improve compliance in women taking oxybutynin hydrochloride for detrusor instability: a pilot study.
    Hooper P; Tincello DG; Richmond DH
    Br J Urol; 1997 Sep; 80(3):414-6. PubMed ID: 9313659
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Medical costs after initiation of drug treatment for overactive bladder: effects of selection bias on cost estimates.
    Nitz NM; Jumadilova Z; Darkow T; Frytak JR; Bavendam T
    Am J Manag Care; 2005 Jul; 11(4 Suppl):S130-9. PubMed ID: 16161386
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.